Filgotinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CHUIKYO (Japan) and DMC (Denmark), among others, recommended or restricted filgotinib, while CIPM (Spain) did not recommend it.
HAS (France) has been harder on filgotinib than on its own caseload: it refused 2 of 5 decisive submissions here (40%), against a base rate of 11% across everything it has assessed.
The record spans 3.2 years, opening at AWMSG (Wales) on 11 Sep 2020 and running to 29 Nov 2023.
HAS (France) changed its position: not recommended on 10 Mar 2021, recommended by 29 Nov 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
7 distinct indication wordings are recorded for filgotinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 26 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess filgotinib, on 11 Sep 2020; HIRA (South Korea) did not open a file until 6 Jul 2023 — a moderate spread of 2.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
8 of the 13 agencies here assessed filgotinib more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
filgotinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for filgotinib reads 13 recommended, 5 restricted, 3 not recommended and 2 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 29 Nov 2023 | Re-assessment of SMR and ASMR | SMR moderate · ASMR V | source |
| DMC (Denmark) | 31 Aug 2023 | Kronisk leddegigt | Direkte indplaceret i behandlingsvejledning | source |
| HIRA (South Korea) | 6 Jul 2023 | 1. 류마티스 관절염 2. 궤양성대장염 | reimbursable only at the evaluated price | source |
| AOTMIT (Poland) | 19 Dec 2022 | Jyseleca reimbursement recommendation | recommended conditionally | source |
| SMC (Scotland) | 10 Oct 2022 | Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modify… | accepted (restricted) | source |
21 further decisions for filgotinib, across 12 agencies, are not shown here. They link to 17 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 26 decisions for filgotinib from 13 agencies, 2020 to 2023. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.